‘Bubble boy’ gene therapy reignites commercial interest

Industry interest reignited by increased safety and efficacy of lentiviral gene therapies in several severe combined immune deficiencies.
Somerville, Massachusetts

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

doi: 10.1038/d41587-019-00015-6
Nature Briefing

Sign up for the daily Nature Briefing email newsletter

Stay up to date with what matters in science and why, handpicked from Nature and other publications worldwide.

Sign Up